NCT03884842View on ClinicalTrials.gov

Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.

PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

October 12, 2022

Study Completion Date

January 17, 2023

Conditions
Asthma
Interventions
BIOLOGICAL

Dupilumab/Dupixent

a monoclonal antibody designed for the treatment asthma and atopic dermatitis.

BIOLOGICAL

Placebo

Matched placebo

Trial Locations (1)

L8N 4A6

Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

McMaster University

OTHER

NCT03884842 - Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma. | Biotech Hunter | Biotech Hunter